Could COMPASS Pathways’ (CMPS) Low-Touch Psilocybin Protocol Quietly Redefine Its Competitive Edge in PTSD?

• Earlier this month, COMPASS Pathways plc reported a post-hoc analysis from an open-label Phase 2 study of its investigational COMP360 synthetic psilocybin treatment in PTSD, showing that administration sessions were characterized by minimal, largely non-directive support with about four-fifths of session time spent in silence.
• The analysis highlights that carefully structured, low-intervention support and a standardized training program for support providers may be central to fostering patient safety, autonomy and consistent implementation of COMP360 across trials in treatment-resistant depression and PTSD.
• Next, we’ll examine how this emphasis on standardized, non-directive support for COMP360 sessions could shape COMPASS Pathways’ broader investment narrative.

Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

COMPASS Pathways Investment Narrative Recap

To own COMPASS Pathways, you need to believe COMP360 can reach approval and meaningful uptake in treatment resistant depression, while the company manages its cash burn and financing needs. The new PTSD analysis reinforces COMPASS’s focus on a reproducible, scalable support model, but does not materially change the near term catalyst, which remains the Phase 3 TRD program and NDA progress, or the biggest risk, which is any delay or disappointment in trial outcomes and regulatory review.

Among recent announcements, the July 7, 2026 Phase 3 COMP006 Part B data in TRD is most relevant here, because it sits alongside the PTSD support findings as part of a broader effort to show COMP360 can be delivered in a standardized way across conditions. While the PTSD analysis speaks to how sessions are supported, the Phase 3 TRD results and rolling NDA submission request remain central to timing, regulatory risk and eventual commercial potential.

Yet even with these positive steps, there is still a real risk investors should be aware of if COMP360’s approval time line or label were to...

Read the full narrative on COMPASS Pathways (it's free!)

COMPASS Pathways’ narrative projects $284.9 million revenue and $53.9 million earnings by 2029. This requires earnings to increase by about $246.3 million from -$192.4 million today.

Uncover how COMPASS Pathways' forecasts yield a $24.47 fair value, a 105% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were previously modeling revenue of about US$670.7 million and earnings of roughly US$242.9 million by 2029, so this new PTSD support data could either reinforce that more bullish view on COMP360’s scalability or prompt a rethink, depending on how you weigh the added execution and regulatory risks around PTSD that we discuss next.

Explore 4 other fair value estimates on COMPASS Pathways - why the stock might be worth just $24.47!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your COMPASS Pathways research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free COMPASS Pathways research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate COMPASS Pathways' overall financial health at a glance.

Looking For Alternative Opportunities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com